Breaking News Instant updates and real-time market news.

VERI

Veritone

$23.93

-0.34 (-1.40%)

, AMZN

Amazon.com

$1,168.36

-6.4 (-0.54%)

13:30
12/26/17
12/26
13:30
12/26/17
13:30

Veritone aiming to compete with Amazon, Google, Barron's says

Veritone's (VERI) quest to compete with Amazon (AMZN), Alphabet (GOOG; GOOGL), Microsoft (MSFT) and other big companies appears to be a "Sisyphean task," according to Barron's. But CEO Chad Steelberg sounded buoyant a day after Veritone acquired Atigeo's intellectual property and data analytics, which the company plans to use to improve its conductor technology, which collects data and routes it to specialized machine learning engines for accurate analysis, the report noted. Reference Link

VERI

Veritone

$23.93

-0.34 (-1.40%)

AMZN

Amazon.com

$1,168.36

-6.4 (-0.54%)

GOOGL

Alphabet Class A

$1,068.86

-1.99 (-0.19%)

GOOG

Alphabet

$1,060.12

-3.51 (-0.33%)

MSFT

Microsoft

$85.51

0.01 (0.01%)

  • 09

    Jan

  • 23

    Jan

  • 07

    Feb

  • 07

    Feb

  • 18

    Mar

VERI Veritone
$23.93

-0.34 (-1.40%)

11/22/17
CHLM
11/22/17
NO CHANGE
Target $31
CHLM
Buy
Veritone price target lowered to $31 from $60 at Craig-Hallum
Craig-Hallum analyst Chad Bennett lowered his price target for Veritone to $31 from $60 following Q3 results and its stock offering. The analyst believes that with the timing of Veritone's offering, the company is close to completing an acquisition or two which would add materially to its revenue profile. Bennett reiterates a Buy rating on the shares.
11/07/17
RILY
11/07/17
DOWNGRADE
Target $15
RILY
Sell
B. Riley FBR double downgrades Veritone to Sell after Q3 miss
B. Riley FBR analyst Sameet Sinha double downgraded Veritone to Sell from Buy after the company reported a miss in Q3. Veritone's traction in its artificial intelligence business is "not meaningful" while the current valuation is not supported by recent execution and low revenue levels, Sinha tells investors in a post-earnings research note. The analyst cut his price target for the shares to $15 from $18. Veritone in premarket trading is down 20%, or $7.16, to $29.51.
11/07/17
RILY
11/07/17
DOWNGRADE
Target $15
RILY
Sell
Veritone downgraded to Sell from Buy at B. Riley FBR
B. Riley FBR analyst Sameet Sinha double downgraded Veritone to Sell from Buy and cut his price target for the shares to $15 from $18 following the company's weaker than expected Q3 results.
09/29/17
ROTH
09/29/17
NO CHANGE
Target $62
ROTH
Buy
Roth Capital says Veritone 'the real deal,' ups price target to $62
Roth Capital analyst Brian Alger noted that Citron's short report on Veritone, which included the opinion that it is not an AI company, knocked the stock down 50%. However, after attending numerous investor meetings with the company over the past few weeks, Alger is convinced Veritone is "the real deal" and is transforming businesses through the orchestration of third party ANI engines. Alger, who said Veritone has been clear in its intentions to utilize M&A and now has a list of over 30 potential targets, thinks that with deal potential incorporated a $1B valuation is "not only reasonable, but could be conservative." He raised his price target on Veritone shares to $62 from $13.20 and keeps a Buy rating on the stock, which closed yesterday at $36.88.
AMZN Amazon.com
$1,168.36

-6.4 (-0.54%)

12/21/17
RBCM
12/21/17
NO CHANGE
Target $1200
RBCM
Outperform
Amazon revenue from Alexa could grow to $10-$11B by 2020, says RBC Capital
RBC Capital analyst Mark Mahaney said the firm's latest annual Alexa survey has left him more convinced of the potential long-term impact the voice-powered devices can have on Amazon. He expects Alexa's value proposition to increase in power as awareness and ownership rise and believes Amazon could see $10B-$11B in Alexa-related revenue by 2020. Mahaney maintains an Outperform rating and $1,200 price target on Amazon shares.
12/22/17
DBAB
12/22/17
NO CHANGE
DBAB
Strategic rationale for Home Depot buying XPO 'very clear,' says Deutsche Bank
Deutsche Bank analyst Amit Mehrotra noted that Recode reported that Home Depot (HD) has held internal talks about a potential acquisition bid for XPO Logistics (XPO), which is also said to be possibly being considered by Amazon (AMZN) as a takeover target. The news highlights the strategic and scarcity value of XPO's assets, said Mehrotra, who believes the company has "by far" the biggest heavy goods last mile business in the country. From a valuation standpoint, the analyst said his $110 price target is conservative and does not include any assumption of corporate tax reform, which would drive his target to $130. He maintains a Buy rating on XPO, whose stock is up 14% to $90 per share heading into the close.
12/26/17
SBSH
12/26/17
NO CHANGE
Target $110
SBSH
Buy
Citi ups XPO target to $110, sees takeover value closer to $120
Citi analyst Christian Wetherbee raised his price target for XPO Logistics (XPO) to $110 from $75 after Recode reported Friday that Home Depot (HD) has contemplated an acquisition of the company, partially as a defensive move to prevent Amazon (AMZN) from doing the same. In a research note titled "Buyer or Seller, There are Lots of Ways to Win," Wetherbee argues that XPO CEO Brad Jacobs is likely to be willing to maximize shareholder value either as a buyer or seller if the opportunity was right. Friday's article likely adds a takeout premium to XPO shares, at least near-term, the analyst adds. His new price target reflects this dynamic along with a "strong fundamental story." The analyst, however, believes a takeout bid would need to be higher, closer to $120 per share, due to the "significant potential value" XPO can create as a standalone company. Wetherbee keeps a Buy rating on XPO shares, which closed Friday up 14%, or $11.32, to $90.01.
12/19/17
KEYB
12/19/17
UPGRADE
Target $21
KEYB
Overweight
Brandywine Realty upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Jordan Sadler upgraded Brandywine Realty (BDN) to Overweight from Sector Weight with a price target of $21. Sadler cites the company's execution in leasing, development discipline, and completion of its disposition program that positions the portfolio for same-store NOI growth that the management forecasts at 2%-5% through 2021. The analyst also notes a potential catalyst in Amazon (AMZN) choosing a location for its HQ2 - if Philadelphia, Austin, or North Virgina are selected, the company could benefit.
GOOGL Alphabet Class A
$1,068.86

-1.99 (-0.19%)

12/13/17
COWN
12/13/17
NO CHANGE
Target $2170
COWN
Outperform
Priceline named a best idea for 2018 at Cowen
Cowen analyst Kevin Kopelman believes Priceline (PCLN) is not shifting away from Google (GOOG, GOOGL). The company is largely aligned with the search giant and should continue to benefit from underlying growth in travel and the shift to online and mobile, Kopelman tells investors in a research note. He believes investor perception has Priceline both slowing down and shifting away from Google. The analyst calls Priceline a top idea for 2018 with an Outperform rating and $2,170 price target.
12/06/17
PIPR
12/06/17
DOWNGRADE
Target $37
PIPR
Underweight
Yelp downgraded to Underweight from Neutral at Piper Jaffray
Piper Jaffray analyst Sam Kemp downgraded Yelp (YELP) to Underweight from Neutral and lowered his price target for the shares to $37 from $38. The stock closed the trading day down $1.02 to $41.88. Given the "messiness" of removing Eat24, investors missed that Yelp lowered organic Q4 guidance by 2%, Kemp tells investors in a research note. He believes the company may guide down 2018 revenue when reporting Q4 results. Further, the analyst thinks Yelp's believe traffic will become more difficult as Facebook (FB) and Google (GOOG, GOOGL) aggressively route traffic to their own offerings. In addition, Kemp does not view Yelp as an acquisition candidate.
12/06/17
12/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alibaba (BABA) initiated with a Positive at Susquehanna. 2. WWE (WWE) initiated with an Overweight at JPMorgan. 3. Facebook (FB), Alphabet Class A (GOOGL), and Amazon.com (AMZN) were initiated with an Outperform at Evercore ISI, while Netflix (NFLX) was initiated with an In Line. 4. Applied Materials (AMAT) initiated with an Outperform at Wells Fargo. 5. Delphi Technologies (DLPH) was initiated with an Overweight at Barclays while being initiated with a Neutral at BofA/Merrill and UBS. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/05/17
EVER
12/05/17
INITIATION
Target $46
EVER
In Line
Yelp initiated with an In Line at Evercore ISI
As reported earlier, Evercore ISI analyst Anthony DiClemente initiated Yelp (YELP) with an In Line rating and a price target of $46. DiClemente says the execution issues are now in the past as investor focus shifts to longer-term fundamentals. While there is runway for advertising penetration among local businesses, the analyst writes in his research note, there is also concern over the longer term about the company's competitive positioning relative to Facebook (FB) and Google (GOOGL). DiClemente believes that given the stock price appreciation of about 13% year-to-date, estimates would have to rise to justify more gains.
GOOG Alphabet
$1,060.12

-3.51 (-0.33%)

12/07/17
COWN
12/07/17
NO CHANGE
COWN
Tax reform should drive upside for internet companies, says Cowen
Cowen analyst John Blackledge said the proposed U.S. tax overhaul should drive earnings upside at Facebook (FB), Amazon (AMZN) and Alphabet (GOOG). He estimates the cut would result in tax savings, leading to increased estimates for the companies and also notes the potential for repatriation to provide a lift.
12/08/17
JPMS
12/08/17
NO CHANGE
JPMS
JPMorgan sees AWS single sign-on having limited impact on Okta
Shares of Okta (OKTA) are trading down after Amazon Web Services (AMZN) introduced its own basic single sign-on solution. JPMorgan analyst Sterling Auty, however, believes the product will not have much of an impact on Okta. Similar to Microsoft (MSFT) Azure, Amazon's product will be good for applications only running in AWS or to control access to a limited number of other SaaS applications, Auty tells investors in a research note. The major advantage for Okta is the ability to control access to all applications regardless of whether they are deployed on premise, in AWS, in Azure, in Google (GOOG, GOOGL), or even a SaaS application like Salesforce (CRM), the analyst contends. He believes Okta's "secret sauce lies in being platform neutral." Auty keeps an Overweight rating on the shares. Okta in morning trading is down 5%, or $1.42, to $27.75.
MSFT Microsoft
$85.51

0.01 (0.01%)

12/20/17
BMOC
12/20/17
NO CHANGE
Target $142
BMOC
Market Perform
Red Hat results solid, but expectations already high, says BMO Capital
BMO Capital analyst Keith Bachman raised his price target on Red Hat (RHT) to $142 from $128, stating that the company's results were solid across all metrics but he believes high expectations overshadowed the strong results. While saying he thinks Red Hat is the best-positioned hybrid cloud provider, valuation leaves him with a Market Perform rating on the stock and a preference toward Microsoft (MSFT) and VMware (VMW) in terms of hybrid cloud stocks.
12/20/17
OPCO
12/20/17
NO CHANGE
Target $100
OPCO
Outperform
Microsoft price target raised to $100 from $92 at Oppenheimer
Oppenheimer analyst Timothy Horan raised his price target for Microsoft to $100 from $92 saying he sees it as the best large-cap stock in his coverage given high operating leverage from accelerating cloud growth. The analyst believes 2018 is going to be "a very strong year" for cloud services and infrastructure, and a better one for legacy telcos. He reiterates an Outperform rating on the shares.
12/12/17
BERN
12/12/17
NO CHANGE
Target $100
BERN
Outperform
Survey shows continued momentum for Microsoft Azure, says Bernstein
Bernstein analyst Mark Moerdler says his firm's IT Hardware semi-annual CIO survey shows that Microsoft (MSFT) Azure continues to gain mindshare and momentum within enterprise IT departments, and that Azure's customer count could be equal to or more than Amazon (AMZN) Web Services among enterprise user, he adds. The analyst notes that the continued momentum fully supports his thesis regarding the Microsoft Commercial Cloud opportunity and should support Azure revenue growth of about 90%, if not faster, for multiple quarters to come. He reiterates an Outperform rating and $100 price target on Microsoft shares.

TODAY'S FREE FLY STORIES

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

15:26
01/20/18
01/20
15:26
01/20/18
15:26
Hot Stocks
Opdivo, Yervoy combo demonstrates activity in patients with dMMR, MSI-H mCRC »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 05

    Feb

  • 08

    Feb

  • 05

    Mar

  • 08

    Mar

EXEL

Exelixis

$28.00

0.14 (0.50%)

, RHHBY

Roche

$30.69

0.18 (0.59%)

15:22
01/20/18
01/20
15:22
01/20/18
15:22
Hot Stocks
Exelixis presents updated results from Phase 1b clinical trial in CRC »

Exelixis (EXEL) announced…

EXEL

Exelixis

$28.00

0.14 (0.50%)

RHHBY

Roche

$30.69

0.18 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 01

    Feb

  • 08

    Feb

  • 15

    Feb

  • 23

    Feb

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

15:17
01/20/18
01/20
15:17
01/20/18
15:17
Hot Stocks
Array BioPharma updates results from BEACON Phase 3 trial »

Array BioPharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

  • 30

    Jun

SO

Southern Company

$44.44

-0.46 (-1.02%)

15:13
01/20/18
01/20
15:13
01/20/18
15:13
Hot Stocks
Southern Company accelerates restoration efforts in Puerto Rico »

Southern Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.43

0.19 (0.65%)

15:10
01/20/18
01/20
15:10
01/20/18
15:10
Hot Stocks
Teck Resources announces Elkview incident »

Teck Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TWTR

Twitter

$23.66

-0.38 (-1.58%)

14:03
01/20/18
01/20
14:03
01/20/18
14:03
Hot Stocks
Twitter begins notifying users exposed to Russian propaganda during elections »

Twitter, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

, SPX

S&P 500

13:58
01/20/18
01/20
13:58
01/20/18
13:58
Periodicals
Government shuts down on anniversary of Trump presidency, Reuters reports »

President's Trump…

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

13:48
01/20/18
01/20
13:48
01/20/18
13:48
Periodicals
NY Times stock jumps after Facebook's announcement, Recode reports »

Facebook (FB) CEO Mark…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

13:36
01/20/18
01/20
13:36
01/20/18
13:36
Periodicals
Still time to shop Walmart shares as company makes changes, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

BA

Boeing

$337.73

-2.43 (-0.71%)

08:50
01/20/18
01/20
08:50
01/20/18
08:50
Periodicals
Boeing not a sell just yet, Barron's says »

Boeing stock has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, EADSY

Airbus

$28.43

0.755 (2.73%)

08:24
01/20/18
01/20
08:24
01/20/18
08:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$178.46

-0.8 (-0.45%)

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$337.73

-2.43 (-0.71%)

VZ

Verizon

$51.91

0.36 (0.70%)

NYT

New York Times

$21.90

1.7 (8.42%)

TWX

Time Warner

$93.36

0.39 (0.42%)

DIS

Disney

$110.59

0.17 (0.15%)

TIME

Time Inc.

$18.55

0.05 (0.27%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

BAC

Bank of America

$31.72

0.24 (0.76%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BK

BNY Mellon

$56.61

1.26 (2.28%)

WLKP

Westlake Chemical Partners

$24.45

-0.1 (-0.41%)

MON

Monsanto

$120.66

1.8 (1.51%)

DLTR

Dollar Tree

$114.73

1.83 (1.62%)

CE

Celanese

$112.96

1.93 (1.74%)

LYB

LyondellBasell

$119.92

3.03 (2.59%)

TSE

Trinseo

$79.45

2.2 (2.85%)

EYE

National Vision

$43.13

1.12 (2.67%)

ETFC

E-Trade

$54.28

0.63 (1.17%)

LPLA

LPL Financial

$59.03

0.53 (0.91%)

AMTD

TD Ameritrade

$55.17

0.21 (0.38%)

SCHW

Charles Schwab

$55.48

0.15 (0.27%)

ADS

Alliance Data

$261.82

5.88 (2.30%)

FISV

Fiserv

$138.11

0.17 (0.12%)

FLT

FleetCor

$206.65

3.4 (1.67%)

HAWK

Blackhawk

$45.25

0.1 (0.22%)

MTZ

MasTec

$53.30

1.25 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 18

    Mar

CME

CME Group

$154.28

2.07 (1.36%)

, GS

Goldman Sachs

$256.12

5.15 (2.05%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Bar Association to hold annual meeting »

Derivatives & Futures…

CME

CME Group

$154.28

2.07 (1.36%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BP

BP

$42.40

-0.5 (-1.17%)

C

Citi

$78.30

0.91 (1.18%)

BAC

Bank of America

$31.72

0.24 (0.76%)

CS

Credit Suisse

$19.06

0.13 (0.69%)

CRL

Charles River

$107.89

1.22 (1.14%)

MS

Morgan Stanley

$57.46

1.62 (2.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 15

    Feb

AMGN

Amgen

$189.28

1.69 (0.90%)

, BAYRY

Bayer

$32.05

0.235 (0.74%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2018 ASCO…

AMGN

Amgen

$189.28

1.69 (0.90%)

BAYRY

Bayer

$32.05

0.235 (0.74%)

BLRX

BioLineRx

$1.09

-0.02 (-1.80%)

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

CELG

Celgene

$102.65

0.93 (0.91%)

DNA

Bought by RHHBY

ESALY

Eisai

$56.88

0.115 (0.20%)

EXEL

Exelixis

$28.00

0.14 (0.50%)

HALO

Halozyme

$17.98

0.13 (0.73%)

INCY

Incyte

$93.16

1.24 (1.35%)

IPSEY

Ipsen

$34.65

0.75 (2.21%)

LXRX

Lexicon

$10.44

0.2 (1.95%)

MGNX

MacroGenics

$19.19

0.3 (1.59%)

MRK

Merck

$61.28

0.15 (0.25%)

NVS

Novartis

$86.94

0.53 (0.61%)

SNY

Sanofi

$44.60

0.09 (0.20%)

ONCY

Oncolytics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 02

    Feb

  • 03

    Feb

  • 05

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 02

    Mar

  • 05

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 30

    Apr

  • 02

    May

  • 17

    May

  • 28

    May

  • 23

    Oct

WLFC

Willis Lease

$26.66

0.05 (0.19%)

18:59
01/19/18
01/19
18:59
01/19/18
18:59
Hot Stocks
Willis Lease announces $1,000 bonus for employees »

Willis Lease announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary at MUFG »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.